Regenova Pharmaceuticals

Regenova leverages AI-driven TRACE™ technology to revolutionize antibody discovery, accelerating drug development and reducing costs for oncology and infectious disease therapies.

1. Signed contract with IBM for Quantum Computer based drug discovery project.
2. MOU signed with Cancer Free Bio (Taiwan) for co drug development.

Regenova targets pharmaceutical companies, biotech firms, and academic research institutions globally, primarily located in North America, Europe, and Asia-Pacific. Our customers are driven by the need to accelerate drug discovery and reduce costs, particularly for oncology and infectious disease therapies, which represent a growing global market valued at over $200 billion annually. With advancements in AI-driven antibody discovery and unmet needs in hard-to-treat diseases, the market is rapidly expanding, with significant opportunities for innovation and investment.

Proving the Problem:
The pharmaceutical industry spends billions annually on R&D, yet most drug candidates fail in clinical trials due to inefficacy or toxicity. This results in wasted time, resources, and lost revenue. Pharma companies seek faster, more reliable methods to optimize drug discovery and reduce risks associated with clinical failures.

Regenova’s TRACE™ platform leverages AI to accelerate antibody creation, ensuring specificity, reduced toxicity, and cost-effectiveness. By addressing critical pain points—such as improving success rates in drug development and reducing timelines—our platform offers unmatched value. Clients are willing to pay for innovative solutions that save time, reduce costs, and improve market readiness for life-saving drugs.

Regenova faces competition from biotech companies like AbCellera, Schrödinger, and Exscientia, which use AI-driven platforms for drug discovery. However, these platforms often focus on small molecules or broad-spectrum solutions, whereas Regenova’s TRACE™ platform specializes in AI-powered antibody discovery, with dual applications in oncology and infectious diseases. Existing alternatives, such as traditional lab-based antibody discovery, are costly, time-consuming, and limited by human capacity, making Regenova’s approach more efficient and scalable.

Regenova stands out with its TRACE™ platform, which leverages AI to rapidly generate highly specific antibodies, significantly reducing discovery costs and timelines. Unlike competitors, Regenova’s dual focus on oncology and infectious diseases, including hard-to-treat cancers and pandemic-ready therapies, addresses critical unmet needs. Additionally, its unique approach to Nanobody Drug Conjugates (NDCs) positions the company as a pioneer in next-generation therapeutic solutions with enhanced efficacy and reduced toxicity.

Revenue Steams-

1. Pharmaceuticals collaboration
2. Grants and Gov organization collaboration
3. Out licensing drugs
4. Royalty

Regenova operates on a hybrid business model, generating revenue through licensing its AI-discovered antibody assets and offering TRACE™ platform-driven drug discovery services to biotech and pharmaceutical companies. This approach ensures steady cash flow from service partnerships while capturing long-term value through royalty agreements and milestone payments from licensed therapeutics.

1. Feasibility testing of the AI model
2. Toxicity Model Prediction and testing
3. Hiring talent for AI and Quantum computing development

$500,000/- asking for 8% equity (SAFE)

Regenova faces risks such as intense competition from established biotech companies with larger resources, potential economic downturns affecting funding, and rapid technological advancements that could outpace its current AI-driven platform. Additionally, unforeseen challenges in regulatory approvals or clinical trials could delay progress. However, Regenova is proactively mitigating these risks by continuously enhancing its TRACE™ platform, staying ahead of technological advancements, and exploring quantum computing for drug discovery to maintain a competitive edge and future-proof its operations.

H7 Biocapital Accelerator, Fall 2024 batch. Program location- Silicon Valley,CA (Virtual)

Participated in H7 Biocapital Accelerator program, Fall 2024 batch.